As of December 2023, 22 cases in which patients treated with approved chimeric antigen receptor (CAR) T-cell therapies developed T-cell malignant neoplasms had been reported to the US Food and Drug Administration, with CAR transgenes detected in malignant clones in three patients. In the phase 3 CARTITUDE-4 trial, patients with lenalidomide-refractory multiple myeloma were treated with ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen-directed CAR T-cell therapy produced by means of lentiviral transduction. The aim of this study was to conduct clinicogenomic characterization of clinically aggressive peripheral T-cell lymphoma–not otherwise specified, referred to as a CAR transgenic T-cell lymphoproliferative neoplasm (CTTLN), that developed in two CARTITUDE-4 participants after cilta-cel infusion.

Effective secondline therapy combinations that include new drug classes are required for patients with relapsed or refractory multiple myeloma (RRMM). In the first interim analysis of the ongoing DREAMM-7 trial (median follow-up 28.2 months), the combination of belantamab mafodotin, bortezomib and dexamethasone (BVd) demonstrated superior progression-free survival over daratumumab, bortezomib and dexamethasone (DVd) in patients with RRMM who had received at least one previous line of therapy (hazard ratio 0.41, 95% confidence interval 0.31–0.53; p<0.001). The aim of this article was to report efficacy data from the second interim analysis of DREAMM-7.

The primary analysis (median follow-up 18.7 months) of the phase 3 BELLINI study in adults with relapsed or refractory multiple myeloma (RRMM) showed that triplet therapy with venetoclax, bortezomib and dexamethasone significantly improved progression-free survival and the overall response rate compared with placebo, bortezomib and dexamethasone. Median overall survival (OS) was not reached in either group, but early mortality was unexpectedly elevated with venetoclax. The aim of this study was to report the final OS analysis of BELLINI.

The current standard of care for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) is triplet therapy with daratumumab, lenalidomide and dexamethasone or bortezomib, lenalidomide and dexamethasone (VRd). The aim of this study was to investigate whether a quadruplet regimen with daratumumab added to VRd (D-VRd) improves efficacy over VRd alone in patients with NDMM who are either ineligible for transplantation or in whom transplantation is not planned as initial therapy (i.e. transplant deferred).